Cargando…

Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma

Esophageal cancer (EC) remains a public health concern with a high mortality and disease burden worldwide. Esophageal squamous cell carcinoma (ESCC) is a predominant histological subtype of EC that has unique etiology, molecular profiles, and clinicopathological features. Although systemic chemother...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ooki, Akira, Osumi, Hiroki, Chin, Keisho, Watanabe, Masayuki, Yamaguchi, Kensei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978325/ https://www.ncbi.nlm.nih.gov/pubmed/36872946 http://dx.doi.org/10.1177/17588359221138377

Ejemplares similares

Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma
por: Ooki, Akira, et al.
Publicado: (2023)

Clinical Progress in Inoperable or Recurrent Advanced Gastric Cancer Treatment from 1004 Single Institute Experiences Between 2007 and 2018
por: Nakayama, Izuma, et al.
Publicado: (2022)

Modified FOLFOX6 as a first-line treatment for patients with advanced gastric cancer with massive ascites or inadequate oral intake
por: Osumi, Hiroki, et al.
Publicado: (2018)

Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second‐line chemotherapy
por: Osumi, Hiroki, et al.
Publicado: (2020)

Correlation between circulating tumor DNA and carcinoembryonic antigen levels in patients with metastatic colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2021)

Efficacy and Safety of Trastuzumab Deruxtecan and Nivolumab as Third- or Later-Line Treatment for HER2-Positive Advanced Gastric Cancer: A Single-Institution Retrospective Study
por: Shimozaki, Keitaro, et al.
Publicado: (2023)

Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab
por: Kamiimabeppu, Daisaku, et al.
Publicado: (2021)

Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors
por: Fukuda, Koshiro, et al.
Publicado: (2023)

Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study
por: Kitagawa, Yusuke, et al.
Publicado: (2019)

Circulating Tumor DNA: The Dawn of a New Era in the Optimization of Chemotherapeutic Strategies for Metastatic Colo-Rectal Cancer Focusing on RAS Mutation
por: Udagawa, Shohei, et al.
Publicado: (2023)

Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study
por: Kitagawa, Yusuke, et al.
Publicado: (2020)

Single-institute comparison of the efficacy of systemic chemotherapy for oesophagogastric junction adenocarcinoma and stomach adenocarscinoma in a metastatic setting
por: Nakayama, Izuma, et al.
Publicado: (2020)

Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research
por: Takahari, Daisuke, et al.
Publicado: (2020)

Treatment Strategy for Esophageal Squamous Cell Carcinoma With Endoscopic Intramural Metastasis
por: Okamura, Akihiko, et al.
Publicado: (2022)

The dawn of precision medicine in diffuse-type gastric cancer
por: Ooki, Akira, et al.
Publicado: (2022)

Treatment features of systemic chemotherapy in young adults with unresectable advanced or recurrent gastric cancer
por: Nakayama, Izuma, et al.
Publicado: (2018)

TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma
por: Bando, Hideaki, et al.
Publicado: (2020)

Safety evaluation of fixed‐dose nivolumab in patients with gastric cancer
por: Iikura, Yusuke, et al.
Publicado: (2022)

Immunotherapy in Colorectal Cancer: Current and Future Strategies
por: Ooki, Akira, et al.
Publicado: (2021)

Circulating Tumor DNA as a Novel Biomarker Optimizing Chemotherapy for Colorectal Cancer
por: Osumi, Hiroki, et al.
Publicado: (2020)

Phase II trial of biweekly cetuximab and irinotecan as third‐line therapy for pretreated KRAS exon 2 wild‐type colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2018)

A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2023)

Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer
por: Yagi, Shusuke, et al.
Publicado: (2018)

Effectiveness of taxanes following nivolumab in patients with advanced esophageal squamous cell carcinoma: a retrospective chart review of patients in ATTRACTION-3
por: Chin, Keisho, et al.
Publicado: (2022)

Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel
por: Fukuda, Naoki, et al.
Publicado: (2018)

Clinical utility of circulating tumor DNA for colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2019)

Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2019)

Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)
por: Okada, Morihito, et al.
Publicado: (2022)

Current Topics in Esophageal Squamous Cell Carcinoma
por: Kurumi, Hiroki, et al.
Publicado: (2020)

Interleukin-6 as a potential molecular target in esophageal squamous cell carcinoma
por: ZHAO, ZHI-FEI, et al.
Publicado: (2016)

Identification and Validation of Esophageal Squamous Cell Carcinoma Targets for Fluorescence Molecular Endoscopy
por: Zhao, Xiaojuan, et al.
Publicado: (2021)

A novel clinical prognostic index for patients with advanced gastric cancer: possible contribution to the continuum of care
por: Shimozaki, K., et al.
Publicado: (2021)

A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma
por: Ooki, Akira, et al.
Publicado: (2022)

Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3)
por: Takahashi, Masanobu, et al.
Publicado: (2020)

Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer
por: Wakatsuki, Takeru, et al.
Publicado: (2018)

Genomic and molecular characterization of esophageal squamous cell carcinoma
por: Lin, De-Chen, et al.
Publicado: (2014)

Two Cases of Long-Term Survival of Advanced Colorectal Cancer with Synchronous Lung Metastases Treated with mFOLFOX6/XELOX + Bevacizumab
por: Ushida, Yuta, et al.
Publicado: (2018)

The Molecular Characterization of Genetic Abnormalities in Esophageal Squamous Cell Carcinoma May Foster the Development of Targeted Therapies
por: Testa, Ugo, et al.
Publicado: (2023)

The Current Evidence on Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
por: Oh, Dongryul, et al.
Publicado: (2020)

Neoadjuvant vs definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma patients
por: Chen, Chih-Yi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_39u5ct5vj05jhoqge7v8f2huci